Immunitybio Hisse

Immunitybio EBITDA

Immunitybio (IBRX) öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 16 Ağu 2026 itibarıyla -241,77 M USD dir. Önceki yılda, EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) -279,99 M USD idi — -13,65% (daha yüksek) bir değişiklik.

EBITDA

-241,77 MUSD

YoY

-13,65%

Son güncelleme:

Immunitybio öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2026 -241,77 M USD dir. Immunitybio öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2025 -279,99 M USD idi. %-13,65 daha yüksek önceki yıla kıyasla azalmaktadır.
Access this data via the Eulerpool API

Immunitybio Hisse senedi analizi

Immunitybio ne yapar? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio, Eulerpool'daki en popüler şirketlerden biridir.

Immunitybio hisse senedi hakkında sık sorulan sorular

Immunitybio şirketinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2026 yılında -241,77 M USD.

Immunitybio öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri -279,99 M USD değerinden -241,77 M USD değerine değişmiş ve bu %-13,65 değişimi temsil etmektedir. Değer önceki yıldan daha yüksek dir.

Eulerpool'da EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) öğesinin Immunitybio değerinin 2006'dan itibaren tam tarihsel gelişimini bulabilirsiniz — yıllık değerler, grafikler ve ayrıntılı analiz ile.

EBITDA, finansal yapı, vergi ortamı ve nakit olmayan amortisman giderleri etkisinden önceki işletme performansını ölçer.

EBITDA = EBIT + Amortisman

EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr)'nin USD, yatırımcılar için kilit bir faktördür. Bu metrikte yapılan değişiklikler temel faktörlerin iyileşmesini veya kötüleşmesini gösterebilir ve hisse senedi fiyatını doğrudan etkiler. Eulerpool'da EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr)'nin Immunitybio değerini tarihsel olarak ve gerçek zamanlı olarak takip edebilirsiniz.

Access this data via the Eulerpool API

Gelir Tablosu — Immunitybio

Tüm Kilit Metrikler — Immunitybio